This page has only limited features, please log in for full access.

Unclaimed
Thomas Reiter
Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, A1090 Vienna, Austria

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 07 July 2021 in COVID
Reads 0
Downloads 0

A novel beta coronavirus that emerged in late December 2019 triggered a global pandemic. Diagnostic methods for rapid identification of infected individuals were established in new biotechnological approaches. Vaccine production and application to individuals and measurement of SARS-CoV-2 antibodies also began. Serum samples from 240 health care workers were collected at three-month intervals over nine months. Indirect SARS-CoV-2 nucleocapsid IgG ELISA tests were used to identify humoral immune responses. All seropositive individuals and those with borderline ELISA values were tested with a specifically generated multipanel nucleocapsid fragment immunoblot. Of the 240 individuals, 24 showed seroconversion in ELISA after experiencing COVID-19. All of them showed a positive reaction against the full-length nucleocapsid protein in the immunoblot. The highest reactivity was seen either against fragment N(100–300) or in a minority against the posterior part N(200–419). In general, the staining pattern of COVID-19 patients showed four phenotypes. In contrast, three individuals classified as borderline by ELISA reacted exclusively with fragments N(1–220) and N(100–300) containing the octamer amino acid sequence FYYLGTGP, which is identical in human coronaviruses sharing this sequence with SARS-CoV-2. These represent a unique and thus fifth phenotype. This work suggests the existence of distinct phenotypic patterns of IgG production towards N-protein subdomains.

ACS Style

Sahra Pajenda; Sebastian Kapps; Thomas Reiter; Raimundo Freire; Veronique Smits; Ludwig Wagner; Daniela Gerges; Wolfgang Winnicki; Gere Sunder-Plassmann; Alice Schmidt. Antibody Response against the SARS-CoV-2 Nucleocapsid Protein and Its Subdomains—Identification of Pre-Immunization Status by Human Coronaviruses with Multipanel Nucleocapsid Fragment Immunoblotting. COVID 2021, 1, 105 -114.

AMA Style

Sahra Pajenda, Sebastian Kapps, Thomas Reiter, Raimundo Freire, Veronique Smits, Ludwig Wagner, Daniela Gerges, Wolfgang Winnicki, Gere Sunder-Plassmann, Alice Schmidt. Antibody Response against the SARS-CoV-2 Nucleocapsid Protein and Its Subdomains—Identification of Pre-Immunization Status by Human Coronaviruses with Multipanel Nucleocapsid Fragment Immunoblotting. COVID. 2021; 1 (1):105-114.

Chicago/Turabian Style

Sahra Pajenda; Sebastian Kapps; Thomas Reiter; Raimundo Freire; Veronique Smits; Ludwig Wagner; Daniela Gerges; Wolfgang Winnicki; Gere Sunder-Plassmann; Alice Schmidt. 2021. "Antibody Response against the SARS-CoV-2 Nucleocapsid Protein and Its Subdomains—Identification of Pre-Immunization Status by Human Coronaviruses with Multipanel Nucleocapsid Fragment Immunoblotting." COVID 1, no. 1: 105-114.

Short review
Published: 06 January 2021 in memo - Magazine of European Medical Oncology
Reads 0
Downloads 0

Summary Monoclonal gammopathy of renal significance (MGRS) encompasses a group of kidney disorders in which a monoclonal immunoglobulin secreted by a B cell or plasma cell clone causes renal damage, without meeting hematological criteria for malignancy. The underlying disorder in patients with MGRS is generally consistent with monoclonal gammopathy of undetermined significance (MGUS). Because of the wide spectrum of MGRS-associated diseases, defined through the location and mechanism of renal injury, it is often challenging to establish the right diagnosis. Kidney biopsy must be considered early; hence, close cooperation between hematologist and nephrologists is crucial in diagnosis and treatment from the beginning to prevent irreversible organ damage. Anti B‑cell or plasma-cell clone directed therapy with cytostatic or immunomodulatory agents can save and ameliorate renal function significantly. This is underlined by the fact that, untreated, MGRS-associated disease shows early recurrence in patients after kidney transplantation.

ACS Style

Thomas Reiter; Maja Nackenhorst. Monoclonal gammopathy of renal significance. memo - Magazine of European Medical Oncology 2021, 14, 98 -102.

AMA Style

Thomas Reiter, Maja Nackenhorst. Monoclonal gammopathy of renal significance. memo - Magazine of European Medical Oncology. 2021; 14 (1):98-102.

Chicago/Turabian Style

Thomas Reiter; Maja Nackenhorst. 2021. "Monoclonal gammopathy of renal significance." memo - Magazine of European Medical Oncology 14, no. 1: 98-102.

Journal article
Published: 14 August 2020 in Journal of Clinical Medicine
Reads 0
Downloads 0

Anemia in chronic kidney disease (CKD) is an almost universal complication of this condition. Fibroblast growth factor 23 (FGF23), a key-player in mineral metabolism, is reportedly associated with anemia and hemoglobin levels in non-dialysis CKD patients. Here, we sought to further characterize this association while taking into account the biologically active, intact fraction of FGF23, iron metabolism, and erythropoietin (EPO). Hemoglobin, EPO, iron, and mineral metabolism parameters, including both intact and c-terminal-FGF23 (iFGF23 and cFGF23, respectively) were measured cross-sectionally in 225 non-dialysis CKD patients (stage 1–5, median eGFR: 30 mL/min./1.73m2) not on erythropoiesis stimulating agents or intravenous iron therapy. Statistical analysis was performed by multiple linear regression. After adjustment for eGFR and other important confounders, only cFGF23 but not iFGF23 was significantly associated with hemoglobin levels and this association was largely accounted for by iron metabolism parameters. cFGF23 but not iFGF23 was also associated with mean corpuscular hemoglobin (MCH) and mean corpuscular volume (MCV), again in dependence on iron metabolism parameters. Similarly, EPO concentrations were associated with cFGF23 but not iFGF23, but their contribution to the association of cFGF23 with hemoglobin levels was marginal. In pre-dialysis CKD patients, the observed association of FGF23 with hemoglobin seems to be restricted to cFGF23 and largely explained by the iron status.

ACS Style

Bernhard Bielesz; Thomas Reiter; Fabian Peter Hammerle; Wolfgang Winnicki; Marija Bojic; Andreas Gleiss; Heidi Kieweg; Franz Ratzinger; Gere Sunder-Plassmann; Rodrig Marculescu. The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans. Journal of Clinical Medicine 2020, 9, 2640 .

AMA Style

Bernhard Bielesz, Thomas Reiter, Fabian Peter Hammerle, Wolfgang Winnicki, Marija Bojic, Andreas Gleiss, Heidi Kieweg, Franz Ratzinger, Gere Sunder-Plassmann, Rodrig Marculescu. The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans. Journal of Clinical Medicine. 2020; 9 (8):2640.

Chicago/Turabian Style

Bernhard Bielesz; Thomas Reiter; Fabian Peter Hammerle; Wolfgang Winnicki; Marija Bojic; Andreas Gleiss; Heidi Kieweg; Franz Ratzinger; Gere Sunder-Plassmann; Rodrig Marculescu. 2020. "The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans." Journal of Clinical Medicine 9, no. 8: 2640.

Other
Published: 26 July 2020
Reads 0
Downloads 0

BackgroundChronic kidney disease patients show a high mortality in case of a SARS-CoV-2 infection. Thus, to be informed on Nephrology personnel’s sero-status might be crucial for patient protection. However, limited information exists about the presence of SARS-CoV-2 antibodies in asymptomatic individuals.MethodsWe examined the seroprevalence of SARS-CoV-2 IgG and IgM antibodies among health care workers of a tertiary care kidney center during the peak phase of the Covid-19 crisis in Austria using an orthogonal test strategy and a total of 12 commercial nucleocapsid protein or spike glycoprotein based assays as well as Western blotting and a neutralization assay.ResultsAt baseline 60 of 235 study participants (25.5%, 95% CI: 20.4-31.5) were judged to be borderline positive or positive for IgM or IgG using a high sensitivity/low specificity threshold in one test system. Follow-up analysis after about two weeks revealed IgG positivity in 12 (5.1%, 95% CI: 2.9-8.8) and IgM positivity in six (2.6%, 95% CI: 1.1-5.6) in at least one assay. 2.1% (95% CI: 0.8-5.0) of health care workers showed IgG nucleocapsid antibodies in at least two assays. By contrast, positive controls with proven Covid-19 showed antibody positivity among almost all test systems. Moreover, serum samples obtained from health care workers did not show SARS-CoV-2 neutralizing capacity, in contrast to positive controls.ConclusionsUsing a broad spectrum of antibody tests the present study revealed inconsistent results for SARS-CoV-2 seroprevalence among asymptomatic individuals, while this was not the case among Covid-19 patients.Trial registration numberCONEC, ClinicalTrials.gov number NCT04347694

ACS Style

Thomas Reiter; Sahra Pajenda; Ludwig Wagner; Martina Gaggl; Johanna Atamaniuk; Barbara Holzer; Irene Zimpernik; Daniela Gerges; Katharina Mayer; Christof Aigner; Robert Strassl; Sonja Jansen-Skoupy; Manuela Födinger; Gere Sunder-Plassmann; Alice Schmidt. Covid-19 serology in nephrology health care workers. 2020, 1 .

AMA Style

Thomas Reiter, Sahra Pajenda, Ludwig Wagner, Martina Gaggl, Johanna Atamaniuk, Barbara Holzer, Irene Zimpernik, Daniela Gerges, Katharina Mayer, Christof Aigner, Robert Strassl, Sonja Jansen-Skoupy, Manuela Födinger, Gere Sunder-Plassmann, Alice Schmidt. Covid-19 serology in nephrology health care workers. . 2020; ():1.

Chicago/Turabian Style

Thomas Reiter; Sahra Pajenda; Ludwig Wagner; Martina Gaggl; Johanna Atamaniuk; Barbara Holzer; Irene Zimpernik; Daniela Gerges; Katharina Mayer; Christof Aigner; Robert Strassl; Sonja Jansen-Skoupy; Manuela Födinger; Gere Sunder-Plassmann; Alice Schmidt. 2020. "Covid-19 serology in nephrology health care workers." , no. : 1.

Journal article
Published: 07 February 2020 in Scientific Reports
Reads 0
Downloads 0

Elevated levels of thyroid-stimulating-hormone (TSH) are associated with reduced glomerular filtration rate (GFR) and increased risk of developing chronic kidney disease even in euthyroid patients. Thyroid hormone replacement therapy has been shown to delay progression to end-stage renal disease in sub-clinically hypothyroid patients with renal insufficiency. However, such associations after kidney transplantation were never investigated. In this study the association of thyroid hormones and estimated GFR (eGFR) in euthyroid patients after kidney transplantation was analyzed. In total 398 kidney transplant recipients were assessed retrospectively and association between thyroid and kidney function parameters at and between defined time points, 12 and 24 months after transplantation, was studied. A significant inverse association was shown for TSH changes and eGFR over time between months 12 and 24 post transplantation. For each increase of TSH by 1 µIU/mL, eGFR decreased by 1.34 mL/min [95% CI, −2.51 to −0.16; p = 0.03], corresponding to 2.2% eGFR decline, within 12 months. At selected time points 12 and 24 months post transplantation, however, TSH was not associated with eGFR. In conclusion, an increase in TSH between 12 and 24 months after kidney transplantation leads to a significant decrease in eGFR, which strengthens the concept of a kidney-thyroid-axis.

ACS Style

Benjamin Schairer; Viktoria Jungreithmayr; Mario Schuster; Thomas Reiter; Harald Herkner; Alois Gessl; Gürkan Sengölge; Wolfgang Winnicki. Effect of Thyroid Hormones on Kidney Function in Patients after Kidney Transplantation. Scientific Reports 2020, 10, 1 -7.

AMA Style

Benjamin Schairer, Viktoria Jungreithmayr, Mario Schuster, Thomas Reiter, Harald Herkner, Alois Gessl, Gürkan Sengölge, Wolfgang Winnicki. Effect of Thyroid Hormones on Kidney Function in Patients after Kidney Transplantation. Scientific Reports. 2020; 10 (1):1-7.

Chicago/Turabian Style

Benjamin Schairer; Viktoria Jungreithmayr; Mario Schuster; Thomas Reiter; Harald Herkner; Alois Gessl; Gürkan Sengölge; Wolfgang Winnicki. 2020. "Effect of Thyroid Hormones on Kidney Function in Patients after Kidney Transplantation." Scientific Reports 10, no. 1: 1-7.

Journal article
Published: 02 October 2019 in PeerJ
Reads 0
Downloads 0

Monoclonal overproduction of kappa and/or lambda light chains might result in renal light chain deposition disease. Light chain associated cast nephropathy and renal AL-amyloidosis represent two further pathologies going along with monoclonal gammopathy of renal significance and multiple myeloma. While cast nephropathy often manifests with acute kidney injury, AL-amyloidosis is rather accompanied with chronic kidney disease. Urine samples were collected from 17 patients with multiple myeloma or monoclonal gammopathy. The urine sediment was stained for cast morphology by H/E and light chain immunofluorescence. Following micro-selection of casts under microscope, proteomic analysis of casts was performed by mass spectrometry. Sucrose gradient sedimentation was employed and light chain architecture examined by immunoblotting. Uromodulin was measured by ELISA in sucrose gradient fractions. Urinary casts were observed of about 30 µm in diameter by H/E staining and under immunofluorescence microscopy. Casts with a diameter of 20 µm were observed as a novel variant. Proteome analysis showed that in addition to the expected light chain variants produced by the malignant clone of plasma cells, also histones such as H2B and cathepsin B were contained. Uromodulin was not detectable in urinary casts of all patients. All eleven patients with lambda light chains showed predominant dimerized light chains in the urine immunoblot. Six patients with kappa light chains presented with predominantly monomeric forms of light chains in the immunoblot. The densitometric evaluated ratio of lambda dimers vs. monomers was significantly higher (2.12 ± 0.75) when compared with the ratio of kappa dimers vs. monomers (0.64 ± 0.47), p = 0.00001. Aggregates of light chains separated in part into denser sucrose fractions. This work on urinary casts and light chains demonstrates that hyaline tubular casts represent a complex formation of protein-protein aggregates with histones and cathepsin B identified as novel cast components. Apart from the proteomic composition of the casts, also the formation of the light chains and aggregates is of relevance. Dimerized light chains, which are typical for lambda paraproteins, might be less dialyzable than monomeric forms and may therefore identify patients less responsive to high cut-off dialysis.

ACS Style

Thomas Reiter; Daniela Knafl; Hermine Agis; Karl Mechtler; Ludwig Wagner; Wolfgang Winnicki. Structural analysis of urinary light chains and proteomic analysis of hyaline tubular casts in light chain associated kidney disorders. PeerJ 2019, 7, e7819 .

AMA Style

Thomas Reiter, Daniela Knafl, Hermine Agis, Karl Mechtler, Ludwig Wagner, Wolfgang Winnicki. Structural analysis of urinary light chains and proteomic analysis of hyaline tubular casts in light chain associated kidney disorders. PeerJ. 2019; 7 ():e7819.

Chicago/Turabian Style

Thomas Reiter; Daniela Knafl; Hermine Agis; Karl Mechtler; Ludwig Wagner; Wolfgang Winnicki. 2019. "Structural analysis of urinary light chains and proteomic analysis of hyaline tubular casts in light chain associated kidney disorders." PeerJ 7, no. : e7819.

Journal article
Published: 24 September 2019 in Scientific Reports
Reads 0
Downloads 0

The plasma soluble urokinase-type plasminogen activator receptor (suPAR) is a biomarker for focal segmental glomerulosclerosis (FSGS), but its value is under discussion because of ambiguous results arising from different ELISA methods in previous studies. The aim of this study was to compare diagnostic performance of two leading suPAR ELISA kits and examine four objectives in 146 subjects: (1) plasma suPAR levels according to glomerular disease (primary, secondary and recurrent FSGS after kidney transplantation, other glomerulonephritis) and in healthy controls; (2) suPAR levels based on glomerular filtration rate; (3) sensitivity and specificity of suPAR for FSGS diagnosis and determination of optimal cut-offs; (4) suPAR as prognostic tool. Patients with FSGS showed significant higher suPAR values than patients with other glomerulonephritis and healthy individuals. This applied to subjects with and without chronic kidney disease. Although both suPARnostic™ assay and Quantikine Human uPAR ELISA Kit exerted high sensitivity and specificity for FSGS diagnosis, their cut-off values of 4.644 ng/mL and 2.789 ng/mL were significantly different. Higher suPAR was furthermore predictive for progression to end-stage renal disease. In summary, suPAR values must be interpreted in the context of population and test methods used. Knowing test specific cut-offs makes suPAR a valuable biomarker for FSGS.

ACS Style

Wolfgang Winnicki; Gere Sunder-Plassmann; Gürkan Sengölge; Ammon Handisurya; Harald Herkner; Christoph Kornauth; Bernhard Bielesz; Ludwig Wagner; Željko Kikić; Sahra Pajenda; Thomas Reiter; Benjamin Schairer; Alice Schmidt. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method. Scientific Reports 2019, 9, 1 -9.

AMA Style

Wolfgang Winnicki, Gere Sunder-Plassmann, Gürkan Sengölge, Ammon Handisurya, Harald Herkner, Christoph Kornauth, Bernhard Bielesz, Ludwig Wagner, Željko Kikić, Sahra Pajenda, Thomas Reiter, Benjamin Schairer, Alice Schmidt. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method. Scientific Reports. 2019; 9 (1):1-9.

Chicago/Turabian Style

Wolfgang Winnicki; Gere Sunder-Plassmann; Gürkan Sengölge; Ammon Handisurya; Harald Herkner; Christoph Kornauth; Bernhard Bielesz; Ludwig Wagner; Željko Kikić; Sahra Pajenda; Thomas Reiter; Benjamin Schairer; Alice Schmidt. 2019. "Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method." Scientific Reports 9, no. 1: 1-9.

Multicenter study
Published: 20 October 2018 in BMC Cancer
Reads 0
Downloads 0

Renal impairment (RI) is a negative prognostic factor in Multiple Myeloma (MM) and affected patients are often excluded from autologous stem cell transplantation (ASCT). However, it remains unclear whether historically inferior outcome data still hold true. From a total of 475 eligible MM patients who had undergone ASCT between 1998 and 2016, 374 were included in this multi-centric retrospective cohort study. Renal function was determined both at the time of MM diagnosis and ASCT by estimated glomerular filtration rate (eGFR according to the MDRD formula, RI defined as eGFR < 60 ml/min/1.73m2). Patients were categorized into 3 groups: A) no RI diagnosis and ASCT, B) RI at diagnosis with normalization before ASCT and C) RI both at the time of diagnosis and ASCT. Log-rank testing was used for overall and progression-free survival (OS, PFS) analysis. While severe RI at MM diagnosis confers a risk of shorter OS, MM progression after ASCT is not affected by any stage of renal failure. It can be concluded that ASCT can be safely carried out in MM patients with mild to moderate RI and should be pro-actively considered in those with severe RI. When comparing all groups, no difference in OS and PFS was found (p = 0.319 and p = 0.904). After further stratification according to the degree of RI at the time of diagnosis, an OS disadvantage was detected for patients with an eGFR < 45 ml/min/m2. PFS was not affected by any RI stage.

ACS Style

Marlies Antlanger; Tobias Dust; Thomas Reiter; Alexandra Böhm; Wolfgang W. Lamm; Max Gornicec; Ella Willenbacher; David Nachbaur; Roman Weger; Werner Rabitsch; Susanne Rasoul-Rockenschaub; Nina Worel; Daniel Lechner; Hildegard Greinix; Felix Keil; Heinz Gisslinger; Hermine Agis; Maria-Theresa Krauth. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. BMC Cancer 2018, 18, 1008 .

AMA Style

Marlies Antlanger, Tobias Dust, Thomas Reiter, Alexandra Böhm, Wolfgang W. Lamm, Max Gornicec, Ella Willenbacher, David Nachbaur, Roman Weger, Werner Rabitsch, Susanne Rasoul-Rockenschaub, Nina Worel, Daniel Lechner, Hildegard Greinix, Felix Keil, Heinz Gisslinger, Hermine Agis, Maria-Theresa Krauth. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. BMC Cancer. 2018; 18 (1):1008.

Chicago/Turabian Style

Marlies Antlanger; Tobias Dust; Thomas Reiter; Alexandra Böhm; Wolfgang W. Lamm; Max Gornicec; Ella Willenbacher; David Nachbaur; Roman Weger; Werner Rabitsch; Susanne Rasoul-Rockenschaub; Nina Worel; Daniel Lechner; Hildegard Greinix; Felix Keil; Heinz Gisslinger; Hermine Agis; Maria-Theresa Krauth. 2018. "Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study." BMC Cancer 18, no. 1: 1008.

Comparative study
Published: 01 March 2018 in Kidney International
Reads 0
Downloads 0

Catheter-related infections and dysfunction are the main catheter complications causing morbidity and mortality in hemodialysis patients. However, there are no consistent data for the choice of catheter lock solutions for tunneled hemodialysis lines. In this prospective, multicenter, randomized, controlled trial, two lock regimens using three commercial catheter lock solutions were compared in 106 hemodialysis patients with a newly inserted tunneled central catheter. In the taurolidine group, TauroLock™-Hep500 was used twice per week and TauroLock™-U25,000 once a week. In the citrate group, a four percent citrate solution was used after each dialysis. Both groups were compared regarding catheter-related infections, catheter dysfunction, and costs. Over a period of 15,690 catheter days, six catheter-related infections occurred in six of 52 patients in the taurolidine group, but 18 occurred in 13 of 54 patients in the citrate group, corresponding to 0.67 and 2.7 episodes of catheter-related infections per 1000 catheter days, respectively (Incidence Rate Ratio 0.25, 95% confidence interval, 0.09 to 0.63). Catheter dysfunction rates were significantly lower in the taurolidine group (18.7 vs. 44.3/1000 catheter days) and alteplase rescue significantly more frequent in the citrate group (9.8 vs. 3.8/1000 catheter days). These differences provided significant catheter-related cost savings of 43% in the taurolidine group vs. citrate group when overall expenses per patient and year were compared. Thus, use of taurolidine-based catheter lock solutions containing heparin and urokinase significantly reduced complications related to tunneled hemodialysis catheters when compared to four percent citrate solution and was overall more cost-efficient.

ACS Style

Wolfgang Winnicki; Harald Herkner; Matthias Lorenz; Ammon Handisurya; Željko Kikić; Bernhard Bielesz; Benjamin Schairer; Thomas Reiter; Farsad Eskandary; Gere Sunder-Plassmann; Guerkan Sengoelge. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters. Kidney International 2018, 93, 753 -760.

AMA Style

Wolfgang Winnicki, Harald Herkner, Matthias Lorenz, Ammon Handisurya, Željko Kikić, Bernhard Bielesz, Benjamin Schairer, Thomas Reiter, Farsad Eskandary, Gere Sunder-Plassmann, Guerkan Sengoelge. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters. Kidney International. 2018; 93 (3):753-760.

Chicago/Turabian Style

Wolfgang Winnicki; Harald Herkner; Matthias Lorenz; Ammon Handisurya; Željko Kikić; Bernhard Bielesz; Benjamin Schairer; Thomas Reiter; Farsad Eskandary; Gere Sunder-Plassmann; Guerkan Sengoelge. 2018. "Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters." Kidney International 93, no. 3: 753-760.

Journal article
Published: 20 December 2017 in Scientific Reports
Reads 0
Downloads 0

Vascular calcification is a component of cardiovascular disease, which is leading cause of death in patients with chronic kidney disease (CKD). A functional assay (T50-test) measuring the propensity of human serum to calcify associates with mortality and cardiovascular events in CKD patients. Calcification propensity is known to increase with CKD stage. We investigated whether the T50 readout is directly dependent on excretory kidney function (eGFR) or rather explained by deranged parameters of bone and mineral metabolism in the course of CKD. T50, along with markers implicated in calcification and mineral metabolism, were measured in a cross-sectional cohort of 118 patients with CKD stage 1–5. Associations of T50 with measured parameters were analysed and partial correlations performed to test to which extent the association of T50 with eGFR can be attributed to variation of these parameters. T50 correlates with eGFR, but serum levels of phosphate and calcium largely explain this association. Phosphate, magnesium, fetuin A, albumin, bicarbonate, and serum cross-laps but not Parathyroid Hormone or Fibroblast Growth Factor 23 are associated with T50 in multivariate adjusted models. These findings indicate that T50 values depend mainly on the concentration of promoters and inhibitors of calcification in serum, but not excretory kidney function.

ACS Style

Bernhard Bielesz; Thomas Reiter; Rodrig Marculescu; Andreas Gleiss; Marija Bojic; Heidi Kieweg; Daniel Cejka. Calcification Propensity of Serum is Independent of Excretory Renal Function. Scientific Reports 2017, 7, 1 -5.

AMA Style

Bernhard Bielesz, Thomas Reiter, Rodrig Marculescu, Andreas Gleiss, Marija Bojic, Heidi Kieweg, Daniel Cejka. Calcification Propensity of Serum is Independent of Excretory Renal Function. Scientific Reports. 2017; 7 (1):1-5.

Chicago/Turabian Style

Bernhard Bielesz; Thomas Reiter; Rodrig Marculescu; Andreas Gleiss; Marija Bojic; Heidi Kieweg; Daniel Cejka. 2017. "Calcification Propensity of Serum is Independent of Excretory Renal Function." Scientific Reports 7, no. 1: 1-5.

Research article
Published: 21 September 2015 in PLoS ONE
Reads 0
Downloads 0

Chronic kidney disease (CKD) is associated with high morbidity and mortality. In many patients CKD is diagnosed late during disease progression. Therefore, the implementation of potential biomarkers may facilitate the early identification of individuals at risk. Trefoil factor family (TFF) peptides promote restitution processes of mucous epithelia and are abundant in the urinary tract. We therefore sought to investigate the TFF peptide levels in patients suffering from CKD and their potential as biomarkers for CKD. We analysed TFF1 and TFF3 in serum and urine of 115 patients with CKD stages 1–5 without dialysis by ELISA. 20 healthy volunteers served as controls. Our results showed, that urinary TFF1 levels were significantly increased with the onset of CKD in stages 1–4 as compared to controls and declined during disease progression (p = 0.003, < 0.001, 0.005, and 0.007. median concentrations: 3.5 pg/mL in controls vs 165.2, 61.1, 17.2, and 15.8 pg/mL in CKD 1–4). TFF1 and TFF3 serum levels were significantly elevated in stages 3–5 as compared to controls (TFF1: p < 0.01; median concentrations: 12.1, 39.7, and 34.5 pg/mL in CKD 3–5. TFF3: p < 0.001; median concentrations: 7.1 ng/mL in controls vs 26.1, 52.8, and 78.8 ng/mL in CKD 3–5). TFF3 excretion was increased in stages 4 and 5 (p < 0.001; median urinary levels: 65.2 ng/mL in controls vs 231.5 and 382.6 ng/mL in CKD 4/5; fractional TFF3 excretion: 6.4 in controls vs 19.6 and 44.1 in CKD 4/5). ROC curve analyses showed, that monitoring TFF peptide levels can predict various CKD stages (AUC urinary/serum TFF > 0.8). In conclusion our results show increased levels of TFF1 and TFF3 in CKD patients with a pronounced elevation of urinary TFF1 in lower CKD stages. Furthermore, TFF1 and TFF3 seems to be differently regulated and show potential to predict various CKD stages, as shown by ROC curve analysis.

ACS Style

Diana Lebherz-Eichinger; Bianca Tudor; Hendrik J. Ankersmit; Thomas Reiter; Martin Haas; Franziska Roth-Walter; Claus G. Krenn; Georg A. Roth. Trefoil Factor 1 Excretion Is Increased in Early Stages of Chronic Kidney Disease. PLoS ONE 2015, 10, e0138312 .

AMA Style

Diana Lebherz-Eichinger, Bianca Tudor, Hendrik J. Ankersmit, Thomas Reiter, Martin Haas, Franziska Roth-Walter, Claus G. Krenn, Georg A. Roth. Trefoil Factor 1 Excretion Is Increased in Early Stages of Chronic Kidney Disease. PLoS ONE. 2015; 10 (9):e0138312.

Chicago/Turabian Style

Diana Lebherz-Eichinger; Bianca Tudor; Hendrik J. Ankersmit; Thomas Reiter; Martin Haas; Franziska Roth-Walter; Claus G. Krenn; Georg A. Roth. 2015. "Trefoil Factor 1 Excretion Is Increased in Early Stages of Chronic Kidney Disease." PLoS ONE 10, no. 9: e0138312.

Journal article
Published: 01 December 2014 in Translational Research
Reads 0
Downloads 0
ACS Style

Diana Lebherz-Eichinger; Daniel A. Klaus; Thomas Reiter; Walter H. Hörl; Martin Haas; Hendrik J. Ankersmit; Claus G. Krenn; Georg A. Roth. Increased chemokine excretion in patients suffering from chronic kidney disease. Translational Research 2014, 164, 433 -443.e2.

AMA Style

Diana Lebherz-Eichinger, Daniel A. Klaus, Thomas Reiter, Walter H. Hörl, Martin Haas, Hendrik J. Ankersmit, Claus G. Krenn, Georg A. Roth. Increased chemokine excretion in patients suffering from chronic kidney disease. Translational Research. 2014; 164 (6):433-443.e2.

Chicago/Turabian Style

Diana Lebherz-Eichinger; Daniel A. Klaus; Thomas Reiter; Walter H. Hörl; Martin Haas; Hendrik J. Ankersmit; Claus G. Krenn; Georg A. Roth. 2014. "Increased chemokine excretion in patients suffering from chronic kidney disease." Translational Research 164, no. 6: 433-443.e2.

Journal article
Published: 01 July 2014 in Bone
Reads 0
Downloads 0

It is a matter of debate whether vascular calcification and bone loss are simultaneously occurring but largely independent processes or whether poor bone health predisposes to vascular calcification, especially in patients with kidney disease. Here we investigated the association between the changes of microarchitecture in weight bearing bone and the extent of coronary artery calcification in patients with chronic renal failure. The bone microarchitecture of the tibia using high-resolution peripheral quantitative computed tomography (HR-pQCT), bone mineral density using dual X-ray absorptiometry (DXA) of the lumbar spine, femoral neck and distal radius as well as coronary artery calcification using multi-slice CT and reported as Agatston score were measured in 66 patients with end-stage renal disease on chronic hemodialysis. Markers of bone turnover, vitamin D status and intact parathyroid hormone (iPTH) were assessed. CAC score was found to be <100 in 39% and ≥100 in 61% of patients. The median [95% CI] total CAC score was 282 [315-2587]. By univariate analysis, significant correlations between CAC and age (R=0.52, p<0.001), weight (R=0.3, p<0.01) and serum cross laps (CTX, R=-0.39, p<0.01) were found, and parameters of bone microarchitecture were numerically but not significantly lower in patients with CAC scores ≥100. In multivariate analysis stratifying for gender and correcting for age, tibial density (Dtot) and bone volume/total volume (BV/TV) were significantly lower in patients with CAC scores ≥100 (p<0.05 for both). Low trabecular bone volume and decreased cortical bone density are associated with coronary artery calcification in dialysis patients.

ACS Style

Daniel Cejka; Michael Weber; Danielle Diarra; Thomas Reiter; Franz Kainberger; Martin Haas. Inverse association between bone microarchitecture assessed by HR-pQCT and coronary artery calcification in patients with end-stage renal disease. Bone 2014, 64, 33 -38.

AMA Style

Daniel Cejka, Michael Weber, Danielle Diarra, Thomas Reiter, Franz Kainberger, Martin Haas. Inverse association between bone microarchitecture assessed by HR-pQCT and coronary artery calcification in patients with end-stage renal disease. Bone. 2014; 64 ():33-38.

Chicago/Turabian Style

Daniel Cejka; Michael Weber; Danielle Diarra; Thomas Reiter; Franz Kainberger; Martin Haas. 2014. "Inverse association between bone microarchitecture assessed by HR-pQCT and coronary artery calcification in patients with end-stage renal disease." Bone 64, no. : 33-38.

Journal article
Published: 01 January 2014 in The Journal of Clinical Endocrinology & Metabolism
Reads 0
Downloads 0

Sclerostin serum levels are increased in patients with chronic kidney disease (CKD). Osteoporosis and CKD often occur simultaneously. Currently antisclerostin antibodies are in clinical development for the treatment of osteoporosis. The objective of this study was to study the renal handling of sclerostin. This was a cross-sectional study. The study was conducted at a university hospital and outpatient renal clinic. One hundred twenty men and women with CKD stage 1-5 participated in the study. Measurements of sclerostin in urine and serum (ELISA), renal function [estimated glomerular filtration rate (eGFR)], electrolytes, α1-microglobulin, PTH, vitamin D, and markers of bone turnover were conducted. Eight human kidney biopsies were stained for sclerostin using immunohistochemistry. Urinary excretion of sclerostin was measured. Urinary sclerostin excretion increased with declining eGFR (R=-0.75, P<.001), from 10.4 (±12.7) pmol/L in patients with eGFR greater than 90 mL/min per 1.73 m2 (CKD stage 1) to 117.9 (±65.4) pmol/L in patients with eGFR less than 15 mL/min per 1.73 m2 (CKD stage 5, P<.001). Fractional excretion of sclerostin increased with declining eGFR (R=-0.83, P<.001) from 0.45% (±0.6%) in CKD 1 to 26.3% (±17.6%) in CKD 5 (P<.001). Fractional excretion of sclerostin correlated with fractional excretion of α1-microglobulin (R=0.82, P<.001). No association between serum sclerostin and fractional excretion of phosphorus was found in a multivariate analysis. Sclerostin was detected in proximal tubular cells, showing a diffuse cytoplasmic staining pattern. Increased sclerostin serum levels in CKD patients are not due to decreased renal elimination. On the contrary, renal elimination increases with declining kidney function. Whether this has consequences on antisclerostin antibody dosing, efficacy, or safety in patients with CKD remains to be determined.

ACS Style

Daniel Cejka; Rodrig Marculescu; Nicolas Kozakowski; Max Plischke; Thomas Reiter; Alois Gessl; Martin Haas. Renal Elimination of Sclerostin Increases With Declining Kidney Function. The Journal of Clinical Endocrinology & Metabolism 2014, 99, 248 -255.

AMA Style

Daniel Cejka, Rodrig Marculescu, Nicolas Kozakowski, Max Plischke, Thomas Reiter, Alois Gessl, Martin Haas. Renal Elimination of Sclerostin Increases With Declining Kidney Function. The Journal of Clinical Endocrinology & Metabolism. 2014; 99 (1):248-255.

Chicago/Turabian Style

Daniel Cejka; Rodrig Marculescu; Nicolas Kozakowski; Max Plischke; Thomas Reiter; Alois Gessl; Martin Haas. 2014. "Renal Elimination of Sclerostin Increases With Declining Kidney Function." The Journal of Clinical Endocrinology & Metabolism 99, no. 1: 248-255.

Multicenter study
Published: 08 June 2012 in Trials
Reads 0
Downloads 0

Data generated with the body composition monitor (BCM, Fresenius) show, based on bioimpedance technology, that chronic fluid overload in hemodialysis patients is associated with poor survival. However, removing excess fluid by lowering dry weight can be accompanied by intradialytic and postdialytic complications. Here, we aim at testing the hypothesis that, in comparison to conventional hemodialysis, blood volume-monitored regulation of ultrafiltration and dialysate conductivity (UCR) and/or regulation of ultrafiltration and temperature (UTR) will decrease complications when ultrafiltration volumes are systematically increased in fluid-overloaded hemodialysis patients.

ACS Style

Manfred Hecking; Marlies Antlanger; Wolfgang Winnicki; Thomas Reiter; Johannes Werzowa; Michael Haidinger; Thomas Weichhart; Hans-Dietrich Polaschegg; Peter Josten; Isabella Exner; Katharina Lorenz-Turnheim; Manfred Eigner; Gernot Paul; Renate Klauser-Braun; Walter H Hörl; Gere Sunder-Plassmann; Marcus D Säemann. Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial. Trials 2012, 13, 79 -79.

AMA Style

Manfred Hecking, Marlies Antlanger, Wolfgang Winnicki, Thomas Reiter, Johannes Werzowa, Michael Haidinger, Thomas Weichhart, Hans-Dietrich Polaschegg, Peter Josten, Isabella Exner, Katharina Lorenz-Turnheim, Manfred Eigner, Gernot Paul, Renate Klauser-Braun, Walter H Hörl, Gere Sunder-Plassmann, Marcus D Säemann. Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial. Trials. 2012; 13 (1):79-79.

Chicago/Turabian Style

Manfred Hecking; Marlies Antlanger; Wolfgang Winnicki; Thomas Reiter; Johannes Werzowa; Michael Haidinger; Thomas Weichhart; Hans-Dietrich Polaschegg; Peter Josten; Isabella Exner; Katharina Lorenz-Turnheim; Manfred Eigner; Gernot Paul; Renate Klauser-Braun; Walter H Hörl; Gere Sunder-Plassmann; Marcus D Säemann. 2012. "Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial." Trials 13, no. 1: 79-79.

Journal article
Published: 01 January 2012 in Clinica Chimica Acta
Reads 0
Downloads 0

Chronic kidney disease (CKD) is a condition associated with inflammation and high levels of uremic toxins and reactive oxygen species. As a counterregulation to systemic stress heat shock proteins (HSP) are increased expressed to minimize cell death and preserve cell integrity by inhibiting apoptotic pathways. The aim of this study was to determine HSP27 and HSP70 concentrations in sera and urine of patients suffering from CKD. Concentrations of HSP27 and HSP70 in urine and serum were determined in 119 patients with CKD stages 1 to 5 and 23 healthy volunteers by using ELISA technique. HSP27 serum levels were significantly elevated in patients suffering from CKD stages 3 to 5 as well as fractional HSP27 excretion in stages 2-5 versus healthy controls. Absolute HSP70 urinary values were significantly elevated in stages 4 and 5 and fractional HSP70 excretion was increased in stage 5 compared to controls. Moreover, ROC curve analysis showed the potential of urine and especially serum HSP levels to identify various stages of CKD. We provide evidence for elevated HSP27 concentrations in serum and urine and increased HSP70 excretion levels in patients suffering from CKD. Moreover, our results show that HSP levels might offer potential to examine the stages of CKD as well as the disease course which could further promote individually adjusted treatment planning.

ACS Style

Diana Lebherz-Eichinger; Hendrik J. Ankersmit; Stefan Hacker; Hubert Hetz; Oliver Kimberger; Elisabeth M. Schmidt; Thomas Reiter; Walter H. Hörl; Martin Haas; Claus G. Krenn; Georg A. Roth. HSP27 and HSP70 serum and urine levels in patients suffering from chronic kidney disease. Clinica Chimica Acta 2012, 413, 282 -286.

AMA Style

Diana Lebherz-Eichinger, Hendrik J. Ankersmit, Stefan Hacker, Hubert Hetz, Oliver Kimberger, Elisabeth M. Schmidt, Thomas Reiter, Walter H. Hörl, Martin Haas, Claus G. Krenn, Georg A. Roth. HSP27 and HSP70 serum and urine levels in patients suffering from chronic kidney disease. Clinica Chimica Acta. 2012; 413 (1-2):282-286.

Chicago/Turabian Style

Diana Lebherz-Eichinger; Hendrik J. Ankersmit; Stefan Hacker; Hubert Hetz; Oliver Kimberger; Elisabeth M. Schmidt; Thomas Reiter; Walter H. Hörl; Martin Haas; Claus G. Krenn; Georg A. Roth. 2012. "HSP27 and HSP70 serum and urine levels in patients suffering from chronic kidney disease." Clinica Chimica Acta 413, no. 1-2: 282-286.

Journal article
Published: 11 April 2011 in Clinica Chimica Acta
Reads 0
Downloads 0

Increased cell death in chronic kidney disease (CKD) by either necrosis or apoptosis has been confirmed by a variety of studies. Possible sources are an inadequate persistent inflammation and ischemia as a consequence of CKD or caused by the underlying renal disease. Detection of total or caspase cleaved cytokeratin 18 (CK-18) is a novel and elegant method to determine necrosis or apoptosis of epithelial cells in the patients' sera and urine. 120 patients with CKD stages 1 to 5 were included in the study. Twenty healthy volunteers served as controls. Total and caspase cleaved CK-18 urine and serum concentrations were determined by ELISA. The concentration of serum total CK-18 was significantly higher in CKD stages 3-5 as compared to the healthy controls. Urinary total CK-18 excretion was increased in patients with CKD 5 compared to controls. A significant correlation between urine total CK18 and urine protein and albumin levels was found. Moreover, ROC curve analysis showed the potential of serum and especially urine total CK-18 levels to predict various CKD stages. We provide evidence for increased total CK-18 serum and urine levels in CKD patients, possibly indicating that epithelial cell necrosis is prevalent in CKD.

ACS Style

Georg A. Roth; Diana Lebherz-Eichinger; Hendrik Jan Ankersmit; Stefan Hacker; Hubert Hetz; Thomas Vukovich; Andrea Perne; Thomas Reiter; Alexander Farr; Walter H. Hörl; Martin Haas; Claus G. Krenn. Increased total cytokeratin-18 serum and urine levels in chronic kidney disease. Clinica Chimica Acta 2011, 412, 713 -717.

AMA Style

Georg A. Roth, Diana Lebherz-Eichinger, Hendrik Jan Ankersmit, Stefan Hacker, Hubert Hetz, Thomas Vukovich, Andrea Perne, Thomas Reiter, Alexander Farr, Walter H. Hörl, Martin Haas, Claus G. Krenn. Increased total cytokeratin-18 serum and urine levels in chronic kidney disease. Clinica Chimica Acta. 2011; 412 (9-10):713-717.

Chicago/Turabian Style

Georg A. Roth; Diana Lebherz-Eichinger; Hendrik Jan Ankersmit; Stefan Hacker; Hubert Hetz; Thomas Vukovich; Andrea Perne; Thomas Reiter; Alexander Farr; Walter H. Hörl; Martin Haas; Claus G. Krenn. 2011. "Increased total cytokeratin-18 serum and urine levels in chronic kidney disease." Clinica Chimica Acta 412, no. 9-10: 713-717.